QL 325
Alternative Names: QL-325Latest Information Update: 08 Jul 2024
At a glance
- Originator QLSF Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia